Colchicine, Bromhexine, and Hymecromone as Part of COVID-19 Treatment-Cold, Warm, Hot

Mitev, Vanyo; Mondeshki, Tsanko; Marinov, Krasimir; Bilyukov, Radoslav

doi:10.9734/bpi/codhr/v10/5310a

Cited by 8 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our clinical experience with COVID-19-related pneumonia and pericardial effusion showed that the treatment and resolution of the symptoms take much longer in an outpatient setting. The effect of colchicine overdose in the present case confirms our hypothesis, that only high-loading and maintenance doses of colchicine can have a pronounced therapeutic effect [ 7 - 9 ].…”

Section: Discussionsupporting

confidence: 89%

“…We have previously shown a five-fold decrease in the mortality rate when our therapeutic regimen with colchicine was used in inpatient settings [ 8 , 9 ]. (Four hundred and fifty-two inpatients were treated with SOC (standard-of-care) + colchicine); 213 inpatients were treated with SOC (control); RR (0.23, 95% CI 0.136-0.387); OR (0.23, 95%CI = 0.1296-0.4068) p< 0.0001.)…”

Section: Discussionmentioning

confidence: 99%

“…It is not the same to give a 2 mg loading dose to a 50 kg patient and to a 100 kg patient. We have avoided these therapeutic issues by applying our treatment formula [ 7 - 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…At least 43 observational studies and randomized clinical trials have been published so far testing the effect and role of colchicine in the treatment of COVID-19; however, the results of these studies have been controversial and far from conclusive [ 5 , 6 ]. One common methodological feature of these studies is that they use a low-loading dose, not exceeding 2 mg daily [ 5 , 9 ].…”

Section: Discussionmentioning

confidence: 99%

“…The maintenance dose is half the loading dose [ 7 , 8 ]. This prevents CS, by decreasing the level of inflammatory markers, including IL-6, C-reactive protein (CRP), and D-dimers, and most importantly reduces the mortality between four and five times of inpatients with COVID-19 [ 9 ]. Here we describe the therapeutic effect of an accidental colchicine overdose on a COVID-19 inpatient with bilateral pneumonia and pericardial effusion.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Effect of an Accidental Colchicine Overdose in a COVID-19 Inpatient With Bilateral Pneumonia and Pericardial Effusion

Mondeshki¹,

Bilyukov²,

Mitev³

2023

Cureus

Self Cite

View full text Add to dashboard Cite

A 32-year-old patient with COVID-19 pneumonia and pericardial effusion mistakenly took 15 mg of colchicine over 10 hours. He developed diarrhea that resolved two days after colchicine was stopped. Remarkably, this single overdose of colchicine, without any additional therapy, resulted in the complete recovery of bilateral pneumonia and pericardial effusion, and the patient was discharged on the hospital day 9th. This case demonstrates the possibility that high colchicine doses may have a major role and a dramatic effect in the treatment of COVID-19 patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

“…It is not the same to give a 2 mg loading dose to a 50 kg patient and to a 100 kg patient. We have avoided these therapeutic issues by applying our treatment formula [ 7 - 9 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Effect of an Accidental Colchicine Overdose in a COVID-19 Inpatient With Bilateral Pneumonia and Pericardial Effusion

Mondeshki¹,

Bilyukov²,

Mitev³

2023

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

Tiholov,

Lilov,

Georgieva

et al. 2024

Immunity Inflam & Disease

Self Cite

View full text Add to dashboard Cite

BackgroundPrevious research done in Bulgaria demonstrated a fivefold reduction in mortality from COVID‐19 with increased doses of colchicine from two hospitals in the country. We report here a further 333 cases of COVID‐19 inpatients, treated with different doses of colchicine and its effect on mortality.Materials and MethodsA case‐control comparison from two additional hospitals was conducted between increased doses of colchicine and added bromhexine to standard of care (SOC) versus current SOC. Risk and odds ratio, as well as subgroup analysis, was conducted with newly reported data, alongside aggregate data from all hospital centers to determine the extent of mortality reduction in COVID‐19 inpatients.ResultsThere was a clear reduction in the mortality of inpatients with increasing doses of colchicine—between twofold and sevenfold. Colchicine loading doses of 4 mg are more effective than those with 2 mg. Despite these doses being higher than the so‐called “standard doses,” colchicine inpatients experienced lower mortality than SOC patients (5.7% vs. 19.53%). This mortality benefit was evident in different age subgroups, with a 4‐mg loading dose of colchicine proving slightly superior to a 2‐mg loading dose. Colchicine led to an overall relative risk reduction of 70.7%, with SOC patients having 3.91 higher odds of death. The safety of the doses was not different than the reported in the summary of product characteristics.ConclusionInpatients in Bulgaria with added colchicine and bromhexine to SOC achieved better clinical and mortality outcomes than those on SOC alone. These results question the World Health Organization—recommended strategy to inhibit viral replication. We posit that our treatment strategy to inhibit the Severe acute respiratory syndrome coronavirus 2 entry into the cell with inhaled bromhexine and the hyperactivated NLRP3 inflammasome with higher doses of colchicine, prevents the development of cytokine storm. The timing of the initiation of treatment seems critical.

show abstract

What is the lowest lethal dose of colchicine?

Mitev

2023

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Colchicine, Bromhexine, and Hymecromone as Part of COVID-19 Treatment-Cold, Warm, Hot

Cited by 8 publications

References 0 publications

Effect of an Accidental Colchicine Overdose in a COVID-19 Inpatient With Bilateral Pneumonia and Pericardial Effusion

Effect of an Accidental Colchicine Overdose in a COVID-19 Inpatient With Bilateral Pneumonia and Pericardial Effusion

Effect of increasing doses of colchicine on the treatment of 333 COVID‐19 inpatients

What is the lowest lethal dose of colchicine?

Contact Info

Product

Resources

About